Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ‐deficient mice

The peroxisome proliferator‐activated receptor‐β (PPARβ) has been implicated in tumorigenesis, but its precise role remains unclear. Here, we show that the growth of syngeneic Pparb wild‐type tumors is impaired in Pparb−/− mice, concomitant with a diminished blood flow and an abundance of hyperplastic microvascular structures. Matrigel plugs containing pro‐angiogenic growth factors harbor increased numbers of morphologically immature, proliferating endothelial cells in Pparb−/− mice, and retroviral transduction of Pparb triggers microvessel maturation. We have identified the Cdkn1c gene encoding the cell cycle inhibitor p57Kip2 as a PPARβ target gene and a mediator of the PPARβ‐mediated inhibition of cell proliferation, which provides a possible mechanistic explanation for the observed tumor endothelial hyperplasia and deregulation of tumor angiogenesis in Pparb−/− mice. Our data point to an unexpected essential role for PPARβ in constraining tumor endothelial cell proliferation to allow for the formation of functional tumor microvessels.

[1]  Béatrice Desvergne,et al.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.

[2]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[3]  T. Willson,et al.  Ligand activation of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes , 2007 .

[4]  T. Willson,et al.  Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. , 2004, The Journal of investigative dermatology.

[5]  A. Krook,et al.  Role of AMP Kinase and PPARδ in the Regulation of Lipid and Glucose Metabolism in Human Skeletal Muscle* , 2007, Journal of Biological Chemistry.

[6]  A. Agarwal,et al.  "Lumen digestion" technique for isolation of aortic endothelial cells from heme oxygenase-1 knockout mice. , 2004, BioTechniques.

[7]  O. Sansom,et al.  PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. , 2004, Oncogene.

[8]  R. Evans,et al.  PPAR delta: a dagger in the heart of the metabolic syndrome. , 2006, The Journal of clinical investigation.

[9]  S. Nielsen,et al.  Identification and localization of aquaporin water channels in human salivary glands. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[10]  W. Wahli,et al.  PPARβ/δ Regulates Paneth Cell Differentiation Via Controlling the Hedgehog Signaling Pathway , 2006 .

[11]  R. Evans,et al.  PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. , 1998, Cell.

[12]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Kristjansen,et al.  Angiogenic synergy of bFGF and VEGF is antagonized by Angiopoietin-2 in a modified in vivo Matrigel assay. , 2004, Microvascular research.

[14]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[15]  M. Tomayko,et al.  Determination of subcutaneous tumor size in athymic (nude) mice , 2004, Cancer Chemotherapy and Pharmacology.

[16]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[17]  Daniel Metzger,et al.  Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice , 2001, The Journal of cell biology.

[18]  M. Knopp,et al.  Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging , 2003, Journal of magnetic resonance imaging : JMRI.

[19]  W. Wahli,et al.  Transcriptional regulation of metabolism. , 2006, Physiological reviews.

[20]  Y. Yoon,et al.  Intramyocardial Transplantation of Autologous Endothelial Progenitor Cells for Therapeutic Neovascularization of Myocardial Ischemia , 2003, Circulation.

[21]  T. Willson,et al.  Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. , 2006, Cancer research.

[22]  S. Okret,et al.  p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. , 1999, Molecular endocrinology.

[23]  R. Evans,et al.  Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Folkman Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[25]  A. Burdick,et al.  The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  D. Nettelbeck,et al.  Cell type specificity of the human endoglin promoter. , 1999, Gene.

[27]  K. Kristiansen,et al.  Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. , 2001, The Journal of investigative dermatology.

[28]  P. Carmeliet Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[29]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[30]  P. Schlag,et al.  Transient expression of SV 40 large T antigen by Cre/LoxP-mediated site-specific deletion in primary human tumor cells. , 1997, Human gene therapy.

[31]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[32]  A. Burdick,et al.  The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. , 2006, Cellular signalling.

[33]  T. Willson,et al.  PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. , 2006, Cell death and differentiation.

[34]  P. Bornstein,et al.  Thrombospondins 1 and 2 function as inhibitors of angiogenesis. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[35]  J. Ward,et al.  Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.

[36]  Rajnish A. Gupta,et al.  Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth , 2004, Nature Medicine.

[37]  W. Wahli,et al.  Critical roles of PPARβ/δ in keratinocyte response to inflammation , 2001 .

[38]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. , 2006, Nature.

[39]  W. Wahli,et al.  Critical roles of PPAR beta/delta in keratinocyte response to inflammation. , 2001, Genes & development.

[40]  R. Evans,et al.  PPARδ: a dagger in the heart of the metabolic syndrome , 2006 .

[41]  A. Burdick,et al.  The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. , 2006, Cellular signalling.

[42]  T. Willson,et al.  PPARβ/δ selectively induces differentiation and inhibits cell proliferation , 2006, Cell Death and Differentiation.

[43]  Bert Vogelstein,et al.  Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Stadler Gemcitabine doublets in advanced urothelial cancer. , 2002, Seminars in oncology.

[45]  J. Ntambi,et al.  Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[47]  S. Chien,et al.  Laminar Flow Activates Peroxisome Proliferator–Activated Receptor-&ggr; in Vascular Endothelial Cells , 2004, Circulation.

[48]  K. Kinzler,et al.  Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. McLauchlan,et al.  A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. , 2005, Biochimica et biophysica acta.

[50]  M. Kreutzer,et al.  Induction of PPARβ and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARβ , 2006 .

[51]  T. Nakajima,et al.  Fenofibrate, a peroxisome proliferator‐activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[52]  Fabian Kiessling,et al.  Comparing Dynamic Parameters of Tumor Vascularization in Nude Mice Revealed by Magnetic Resonance Imaging and Contrast‐Enhanced Intermittent Power Doppler Sonography , 2003, Investigative radiology.

[53]  B. Teicher,et al.  Murine Endothelial Cell Lines as Models of Tumor Endothelial Cells , 2004, Clinical Cancer Research.

[54]  T. Willson,et al.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. , 2007, Cellular signalling.

[55]  W. Wahli,et al.  PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. , 2006, Gastroenterology.

[56]  Tasuku Honjo,et al.  Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. , 2004, Genes & development.

[57]  T. Willson,et al.  Peroxisome Proliferator-Activated Receptor (PPAR)-β/δ Stimulates Differentiation and Lipid Accumulation in Keratinocytes , 2004 .

[58]  M. Andreeff,et al.  Differential tumor suppressor properties and transforming growth factor-β responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation , 2007, Oncogene.

[59]  Marios C. Papadopoulos,et al.  Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption , 2005, Nature.

[60]  Stephen P. H. Alexander,et al.  Peroxisome proliferator activated , 2006 .

[61]  J. Peters,et al.  Peroxisome Proliferator-activated Receptor-β/δ Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity* , 2005, Journal of Biological Chemistry.

[62]  O. Sansom,et al.  PPARδ status and Apc-mediated tumourigenesis in the mouse intestine , 2004, Oncogene.

[63]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[64]  J. Ward,et al.  Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. , 2004, Nature medicine.

[65]  O. Sato,et al.  Dual Promoter Structure of Mouse and Human Fatty Acid Translocase/CD36 Genes and Unique Transcriptional Activation by Peroxisome Proliferator-activated Receptor α and γ Ligands* , 2002, The Journal of Biological Chemistry.

[66]  William A. Boisvert,et al.  Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ , 2003, Science.

[67]  W. Wahli,et al.  Differentiation of Trophoblast Giant Cells and Their Metabolic Functions Are Dependent on Peroxisome Proliferator-Activated Receptor β/δ , 2006, Molecular and Cellular Biology.

[68]  O. Sato,et al.  Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands. , 2002, The Journal of biological chemistry.